Syndax Pharmaceuticals SNDX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's operating income?
- Syndax Pharmaceuticals (SNDX) reported operating income of -$34.2M in Q1 2026.
- How has Syndax Pharmaceuticals's operating income changed year-over-year?
- Syndax Pharmaceuticals's operating income increased by 59.2% year-over-year, from -$83.76M to -$34.2M.
- What is the long-term trend for Syndax Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's operating income has grown at a 79.6% compound annual growth rate (CAGR), from $26.22M to -$273.08M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.